Summary
- AstraZeneca’s stock dipped 5.8% in August, the biggest monthly fall in 2022, raising the question whether it is a good time to buy the otherwise high-performing stock on dip.
- Factors like relatively better performance by healthcare stocks in the current sluggish economy and markets, the company's geographical diversification, strong pricing power, and healthy financials work in its favor.
- Its higher than the average sector P/E suggests that it could be advantageous to wait for a better price, but it's a good investment even now going by earnings projections.
For further details see:
AstraZeneca: Buy On The Dip